Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages 514-519

  Morishima, Yoshiyuki ^a   Honda, Yuko ^a   Kamisato, Chikako ^a   Tsuji, Naoki ^a   Kita, Akemi ^a   Edo, Naoko ^a   Shibano, Toshiro ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Bleeding time prolongation dose; ED50; Oral anticoagulant

Indexed keywords

EDOXABAN; ENOXAPARIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; INFERIOR CAVA VEIN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN CONTENT; PROTHROMBIN TIME; RAT; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTATICS; MALE; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 84865251855     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.05.008     Document Type: Article

References (16)

1. H. Van Aken, C. Bode, H. Darius, C. Diehm, A. Encke, and D.C. Gulba Anticoagulation: the present and future Clin Appl Thromb Hemost 7 2001 195 204
2. Hirsh J. Heparin N Engl J Med 324 1991 1565 1574
3. J.I. Weitz Low-molecular-weight-heparins N Engl J Med 337 1997 688 698
4. K.A. Bauer Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa J Thromb Haemost 9 Suppl. 1 2011 12 19
5. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, and T. Nagahara DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J Thromb Haemost 6 2008 1542 1549
6. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Masumoto, T. Oguma, and M. Kojima Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
7. T. Fuji, C.J. Wang, S. Fujita, S. Tachibana, Y. Kawai, and Y. Koretsune Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 Trial Pathophysiol Haemost Thromb 37 2010 A20 [OC297]
8. S. Fujita, T. Fuji, S. Tachibana, Nakamura, and Y. Kawai Safety and efficacy of edoxaban in patients undergoing hip fracture surgery Pathophysiol Haemost Thromb 37 2010 A95 [P366]
9. T. Fuji, S. Fujita, S. Tachibana, Y. Kawai, Y. Koretsune, and T. Yamashita Efficacy and Safety of Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty: STARS J-V trial Blood 116 2010 [Abstract 3320]
10. C.T. Ruff, R.P. Giugliano, E.M. Antman, S.E. Crugnale, T. Bocanegra, and M. Mercuri Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
11. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats Thromb Haemost 98 2007 333 338
12. S.M. Lavelle, and M.M. Iomhair The reliability of thrombotic tendency measured by intravascular wires in the rat Thromb Res 87 1997 353 357
13. Y. Morishima, K. Tanabe, Y. Terada, T. Hara, and S. Kunitada Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants Thromb Haemost 78 1997 1366 1371
14. R.J. Leadley Jr. Coagulation factor Xa inhibition: biological background and rationale Curr Top Med Chem 1 2001 151 159
15. M.M. Levi, E. Eerenberg, E. Löwenberg, and P.W. Kamphuisen Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management Neth J Med 68 2010 68 76
16. T. Fukuda, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents Thromb Haemost 107 2011 253 259